Your session is about to expire
← Back to Search
Digital Storytelling for Cancer Screening Prevention
N/A
Waitlist Available
Led By Mark Weiland, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
For breast cancer screening: age 40-74 years
For cervical cancer screening: age 21-65 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
This trial studies how a digital storytelling intervention can help Latino people get more cancer screenings.
Who is the study for?
This trial is for Hispanic or Latino individuals who need cancer screenings and have visited Hennepin Healthcare, Mountain Park Health Center, or Mayo Clinic in the last year. It's for those aged 40-74 for breast cancer screening, 45-75 for colorectal, and 21-65 for cervical. People with past cancer diagnoses or polyp surveillance (for colorectal) can't join.Check my eligibility
What is being tested?
The 'Stories for Change' digital storytelling intervention aims to encourage cancer screening among Hispanic/Latino communities by sharing relatable stories. The study will assess how well people like this approach and if it affects their behavior towards getting screened.See study design
What are the potential side effects?
Since this is a digital storytelling intervention aimed at prevention through increasing awareness rather than a medical treatment, there are no direct physical side effects associated with participating in this clinical trial.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 40 and 74 years old.
Select...
I am between 21 and 65 years old.
Select...
I am between 45 and 75 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of participants screened and recruited
Secondary outcome measures
Constructs associated with effective implementation research
Trial Design
1Treatment groups
Experimental Treatment
Group I: Stories for Change: Prevention (S4C) interventionExperimental Treatment1 Intervention
Participants who are due or overdue for cancer screening will receive the digital storytelling intervention and complete a cross-sectional survey to assess intervention acceptability, socio-behavioral constructs, and theory-based constructs.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Digital Storytelling Intervention
2019
N/A
~560
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,245 Previous Clinical Trials
3,783,390 Total Patients Enrolled
1 Trials studying Prevention
50 Patients Enrolled for Prevention
Mark Weiland, MDPrincipal InvestigatorMayo Clinic
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have not been diagnosed with cancer but was under surveillance for polyps.I am between 40 and 74 years old.I visited my primary care doctor within the last year.I can choose to join more than one part of this study if I qualify.I am between 45 and 75 years old.I have had breast, cervical, or colorectal cancer before.I am between 21 and 65 years old.My records show I'm due for breast, cervical, or colorectal cancer screening.
Research Study Groups:
This trial has the following groups:- Group 1: Stories for Change: Prevention (S4C) intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger